|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of ABT-199 that can be given patients with relapsed or refractory CLL, NHL, or
SLL. The safety of this drug will also be studied.
ABT-199 is designed to block a critical protein that the leukemia cells need to
survive, which may kill cancer cells and shrink tumors. This is the first study
using ABT-199 in humans.